by Gemma Escarré,
Archivel Farma, owner of the therapeutic vaccine targeting tuberculosis Ruti®, and Laboratorios Silanes, one of the major Mexican pharmaceutical companies, have signed a collaboration agreement for the clinical development and commercialization of the vaccine in Mexico.
Ruti® was designed as a therapeutic vaccine for the treatment (not prevention) of different forms of tuberculosis (TB), meant mainly as a solution to treat Multidrug-Resistant Tuberculosis and as coadjuvant for the standard antibiotic treatment to avoid the frequent relapses associated with TB. The vaccine was originally designed by Dr. Pere-Joan Cardona, Head of the Experimental Tuberculosis Unit at the Institut Germans Trias i Pujol (IGTP) in Badalona and founder and scientific advisor at Archivel. The agreement has been managed by TrifermedCBDO.
Archivel and Trifermed are members of CataloniaBio & HealthTech.
Photo: Olga Rue, general manager of Archivel Farma - © Archivel Farma